ID   K1
AC   CVCL_2537
SY   K-1
DR   BTO; BTO:0006405
DR   CLO; CLO_0007052
DR   CLDB; cl2988
DR   AddexBio; C0025003/51
DR   BCRJ; 0292
DR   BioSample; SAMN03151643
DR   cancercelllines; CVCL_2537
DR   Cosmic; 928833
DR   Cosmic; 1084280
DR   Cosmic; 1132597
DR   Cosmic; 1162845
DR   Cosmic; 1239966
DR   Cosmic; 1280046
DR   Cosmic; 1507368
DR   Cosmic; 1533546
DR   Cosmic; 1536121
DR   Cosmic; 1889001
DR   Cosmic; 2036691
DR   Cosmic; 2319846
DR   Cosmic; 2613254
DR   Cosmic; 2791088
DR   ECACC; 92030501
DR   IARC_TP53; 25012
DR   PharmacoDB; K1_720_2019
DR   Wikidata; Q54899238
RX   PubMed=9054892;
RX   PubMed=17725429;
RX   PubMed=18713817;
RX   PubMed=19087340;
RX   PubMed=20143388;
RX   PubMed=22087789;
RX   PubMed=23162534;
RX   PubMed=25675381;
RX   PubMed=30737244;
CC   Problematic cell line: Contaminated. Shown to be a GLAG-66 derivative (PubMed=19087340; PubMed=20143388).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00218.
CC   Population: Caucasian; Italian.
CC   Doubling time: 24 hours (PubMed=9054892).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): ECACC; PubMed=18713817; PubMed=23162534; PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,14
ST   D16S539: 11,12
ST   D18S51: 18
ST   D21S11: 30,31.2
ST   D2S1338: 20,23
ST   D3S1358: 18
ST   D5S818: 10,11
ST   D7S820: 11
ST   D8S1179: 15
ST   FGA: 21,24
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9918 ! GLAG-66
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
RX   PubMed=9054892; DOI=10.1016/S0360-3016(96)00449-X;
RA   Challeton C., Branea F., Schlumberger M., Gaillard N., de Vathaire F.,
RA   Badie C., Antonini P., Parmentier C.;
RT   "Characterization and radiosensitivity at high or low dose rate of
RT   four cell lines derived from human thyroid tumors.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 37:163-169(1997).
RX   PubMed=17725429; DOI=10.1089/thy.2007.0097;
RA   Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V.,
RA   Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R.,
RA   Trovisco V., Cirnes L., Alves C., Velho S., Soares P.,
RA   Sobrinho-Simoes M.;
RT   "Molecular and genotypic characterization of human thyroid follicular
RT   cell carcinoma-derived cell lines.";
RL   Thyroid 17:707-715(2007).
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
RX   PubMed=19087340; DOI=10.1186/1471-2407-8-371;
RA   Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.;
RT   "Conventional and molecular cytogenetics of human non-medullary
RT   thyroid carcinoma: characterization of eight cell line models and
RT   review of the literature on clinical samples.";
RL   BMC Cancer 8:371.1-371.11(2008).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=22087789; DOI=10.1186/1755-8166-4-26;
RA   Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.;
RT   "Centrosomal and mitotic abnormalities in cell lines derived from
RT   papillary thyroid cancer harboring specific gene alterations.";
RL   Mol. Cytogenet. 4:26.1-26.8(2011).
RX   PubMed=23162534; DOI=10.3389/fendo.2012.00133;
RA   Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A.,
RA   van Staveren W.C.G., Maenhaut C.;
RT   "Thyroid cancer cell lines: an overview.";
RL   Front. Endocrinol. 3:133.1-133.9(2012).
RX   PubMed=25675381; DOI=10.1210/jc.2014-2764;
RA   von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J.,
RA   Tun H.W., Smallridge R.C., Copland J.A. III;
RT   "Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals
RT   stearoyl CoA desaturase 1 as a novel therapeutic target.";
RL   J. Clin. Endocrinol. Metab. 100:E697-E709(2015).
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).